Compare RELY & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | IBRX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2021 | N/A |
| Metric | RELY | IBRX |
|---|---|---|
| Price | $14.59 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $26.00 | $9.71 |
| AVG Volume (30 Days) | 3.3M | ★ 14.5M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,544,865,000.00 | $82,555,000.00 |
| Revenue This Year | $30.78 | $667.18 |
| Revenue Next Year | $18.39 | $88.32 |
| P/E Ratio | $155.13 | ★ N/A |
| Revenue Growth | 31.27 | ★ 1025.95 |
| 52 Week Low | $12.08 | $1.83 |
| 52 Week High | $27.32 | $4.27 |
| Indicator | RELY | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 52.78 |
| Support Level | $14.43 | $2.00 |
| Resistance Level | $14.78 | $2.50 |
| Average True Range (ATR) | 0.51 | 0.14 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 58.78 | 53.00 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.